About Envision Healthcare (NYSE:EVHC)
Envision Healthcare Corporation, through its subsidiaries, provides various healthcare services in the United States. The company operates through two segments, Physician Services and Ambulatory Services. As of December 31, 2017, its physician-led services encompassed providers at approximately 1,800 clinical departments at healthcare facilities in 45 states and the District of Columbia that include emergency department and hospitalist, anesthesiology, radiology/tele-radiology, and children's services. The company also offers ambulatory surgical centers (ASCs) services that provide surgical procedures across multiple specialties, including gastroenterology, ophthalmology, orthopedics, and others. It operated 264 ASCs in 35 states and the District of Columbia. In addition, it provides surgery services, such as management, oversight, and surgeon staffing for trauma surgery services; offers direct patient care and care coordination by clinicians outside the acute care setting through physician-led post-acute care services; and operates office-based medical practices that primarily focus on women's health, as well as provides physician staffing and related management services. Further, it offers medical transportation services in 41 states and the District of Columbia. The company offers its clinical solutions for health systems, payors, providers, and patients. Envision Healthcare Corporation was founded in 1992 and is based in Nashville, Tennessee.
Industry, Sector and Symbol
Industry Offices & clinics of medical doctors
Trailing P/E Ratio15.08
Forward P/E Ratio11.20
Sales & Book Value
Annual Sales$12.18 billion
Price / Sales0.37
Cash Flow$6.1127 per share
Price / Cash6.12
Book Value$59.24 per share
Price / Book0.63
EPS (Most Recent Fiscal Year)$2.48
Return on Equity4.62%
Return on Assets1.90%
Envision Healthcare (NYSE:EVHC) Frequently Asked Questions
What is Envision Healthcare's stock symbol?
Envision Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVHC."
How will Envision Healthcare's stock buyback program work?
Envision Healthcare announced that its board has initiated a share repurchase plan on Tuesday, September 19th 2017, which authorizes the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 4.5% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its shares are undervalued.
How were Envision Healthcare's earnings last quarter?
Envision Healthcare (NYSE:EVHC) announced its quarterly earnings data on Tuesday, February, 27th. The company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.45 by $0.14. The business earned $2 billion during the quarter, compared to the consensus estimate of $1.97 billion. Envision Healthcare had a positive return on equity of 4.62% and a negative net margin of 2.52%. The company's quarterly revenue was up 68.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.15 EPS. View Envision Healthcare's Earnings History.
When is Envision Healthcare's next earnings date?
What guidance has Envision Healthcare issued on next quarter's earnings?
Envision Healthcare issued an update on its FY18 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of $3.46 to $3.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.31. The company issued revenue guidance of $8.35 billion to $8.53 billion, compared to the consensus revenue estimate of $8.30 billion.Envision Healthcare also updated its Q1 guidance to $0.61 to $0.67 EPS.
What price target have analysts set for EVHC?
14 Wall Street analysts have issued 1-year price objectives for Envision Healthcare's stock. Their predictions range from $31.00 to $50.00. On average, they expect Envision Healthcare's share price to reach $40.6071 in the next twelve months. View Analyst Ratings for Envision Healthcare.
What are Wall Street analysts saying about Envision Healthcare stock?
Here are some recent quotes from research analysts about Envision Healthcare stock:
- 1. Canaccord Genuity analysts commented, "We reiterate our BUY rating and raise our PT to $46 based on an improving financial outlook given restructuring and easing utilization headwinds. The company characterized guidance as highly visible and not heroic. As such, we recommend continued exposure as utilization headwinds dissipate and the operational improvement plan takes hold. Key positive: High visibility into 2018 guidance: The low-end of 2018 adj-EBITDA of $960M is 87% in hand when annualizing 4Q’17. M&A from 2017 and 2018 should contribute an incremental $10-$15M and $20-$30M, respectively, bringing visibility up to 92% coverage at the low-end. Organic growth and further expense benefits from operational improvements would be the last leg in getting to guidance. Key negative: Consolidated organic growth rate lowered to 2-5% (was 3-6%) taking into account a softer utilization environment." (2/28/2018)
- 2. Cantor Fitzgerald analysts commented, "Revised 2018 estimates. We are lowering our 2018 adjusted EPS estimate to $3.75 from $3.95 and bringing down our adjusted 2018 EBITDA estimate to $950.6 million from $982 million to account for slightly higher seasonality, primarily in terms of salary, wages and benefits, which account for the majority of EVHC’s operating expenses. Our new estimate is just below the $960 million midpoint of management’s potential 2018 performance, as outlined in a presentation last November, but it remains above the $925.1 million FactSet consensus." (2/21/2018)
- 3. According to Zacks Investment Research, "Envision Healthcare's stock has outperformed the industry in last one month. The company has taken some discrete actions which are expected to improve its operating performance and realize $50 million of incremental adjusted EBITDA in 2018. It is optimistic about the physician services market, which is witnessing consolidation. Also the divestiture of its AMR business will help the company to focus on its core operations. The company is aggressively shifting its payor contract to in-network from out of network which will lead to greater client and patient satisfaction, competitive differentiation, administrative efficiency, enhanced collections and an accelerated cash flow. But, it suffers from high indebtedness, consequently leading to an increase in the interest ratio. Also, its operating expense is on the rise and is exceeding the revenue growth to have exerted pressure on the operating margins." (1/2/2018)
Are investors shorting Envision Healthcare?
Envision Healthcare saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 24,458,190 shares, an increase of 12.8% from the March 15th total of 21,681,282 shares. Based on an average daily volume of 2,365,494 shares, the days-to-cover ratio is currently 10.3 days. Currently, 20.7% of the shares of the company are short sold.
Who are some of Envision Healthcare's key competitors?
Some companies that are related to Envision Healthcare include WellCare (WCG), bluebird bio (BLUE), STERIS (STE), Seattle Genetics (SGEN), Bio-Rad Laboratories (BIO), SAGE Therapeutics (SAGE), Valeant Pharmaceuticals International (VRX), AveXis (AVXS), Alkermes (ALKS), Neurocrine Biosciences (NBIX), West Pharmaceutical Services (WST), ICON (ICLR), Stada Arzneimittel (STDAF), Dexcom (DXCM), Exelixis (EXEL), Valeant Pharmaceuticals International (VRX), athenahealth (ATHN) and Hill-Rom (HRC).
Who are Envision Healthcare's key executives?
Envision Healthcare's management team includes the folowing people:
- Mr. William A. Sanger, Exec. Chairman (Age 68)
- Mr. Christopher A. Holden, CEO, Pres & Director (Age 54)
- Ms. Claire M. Gulmi, Advisor (Age 64)
- Mr. Kevin D. Eastridge, Exec. VP & CFO (Age 53)
- Mr. Karey Lynn Witty, Exec. VP & COO (Age 53)
Has Envision Healthcare been receiving favorable news coverage?
Media stories about EVHC stock have trended somewhat positive on Saturday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Envision Healthcare earned a media sentiment score of 0.14 on Accern's scale. They also assigned media stories about the company an impact score of 45.98 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Envision Healthcare?
Shares of EVHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Envision Healthcare's stock price today?
One share of EVHC stock can currently be purchased for approximately $37.41.
How big of a company is Envision Healthcare?
Envision Healthcare has a market capitalization of $4.59 billion and generates $12.18 billion in revenue each year. The company earns $-228,000,000.00 in net income (profit) each year or $2.48 on an earnings per share basis. Envision Healthcare employs 69,300 workers across the globe.
How can I contact Envision Healthcare?
Envision Healthcare's mailing address is 1A BURTON HILLS BOULEVARD, NASHVILLE TN, 37215. The company can be reached via phone at 615-665-1283 or via email at [email protected]
MarketBeat Community Rating for Envision Healthcare (EVHC)MarketBeat's community ratings are surveys of what our community members think about Envision Healthcare and other stocks. Vote "Outperform" if you believe EVHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Envision Healthcare (NYSE:EVHC) Price Target and Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
14 Wall Street analysts have issued ratings and price targets for Envision Healthcare in the last 12 months. Their average twelve-month price target is $40.6071, suggesting that the stock has a possible upside of 8.55%. The high price target for EVHC is $50.00 and the low price target for EVHC is $31.00. There are currently 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.57||2.57||2.60||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$40.6071||$40.6071||$38.6429||$73.30|
|Price Target Upside: ||8.55% upside||3.04% upside||10.66% upside||76.84% upside|
Envision Healthcare (NYSE:EVHC) Consensus Price Target History
Envision Healthcare (NYSE:EVHC) Analyst Ratings History
(Data available from 4/21/2016 forward)
Envision Healthcare (NYSE:EVHC) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Envision Healthcare (NYSE EVHC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.10%
Envision Healthcare (NYSE EVHC) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/3/2017||Robert Jon Coward||Insider||Sell||1,500||$62.69||$94,035.00||97,863|| |
|6/22/2017||Robert Jon Coward||Insider||Sell||1,500||$60.00||$90,000.00||99,363|| |
|5/3/2017||Robert Jon Coward||Insider||Sell||1,500||$60.53||$90,795.00||114,363|| |
|4/3/2017||Robert Jon Coward||Insider||Sell||1,500||$61.34||$92,010.00||115,863|| |
|3/10/2017||John Thomas Gawaluck||Director||Buy||1,500||$66.65||$99,975.00||6,080|| |
|3/1/2017||Robert Jon Coward||Insider||Sell||1,500||$65.00||$97,500.00||104,319|| |
|10/5/2015||Leonard M Riggs Jr||Director||Sell||4,000||$36.24||$144,960.00||32,179|| |
|9/15/2015||Randel G Owen||CFO||Sell||20,000||$42.00||$840,000.00||367,683|| |
|9/14/2015||William A. Sanger||CEO||Sell||175,000||$41.06||$7,185,500.00|| |
|8/17/2015||Randel G Owen||CFO||Sell||140,000||$44.22||$6,190,800.00|| |
|8/17/2015||Todd G Zimmerman||CEO||Sell||180,000||$44.21||$7,957,800.00|| |
|7/6/2015||Leonard M Riggs Jr||Director||Sell||4,000||$39.32||$157,280.00|| |
|6/25/2015||Dighton Packard||Insider||Sell||40,000||$40.00||$1,600,000.00|| |
|4/20/2015||Dighton Packard||Insider||Sell||240,188||$39.44||$9,473,014.72|| |
|4/16/2015||Horne Edward Van||Insider||Sell||10,000||$40.00||$400,000.00|| |
|4/16/2015||William A Sanger||CEO||Sell||418,500||$40.00||$16,740,000.00|| |
|4/13/2015||Craig A Wilson||SVP||Sell||18,600||$39.57||$736,002.00|| |
|4/13/2015||Leonard M Riggs Jr||Director||Sell||4,000||$39.57||$158,280.00|| |
|3/19/2015||Horne Edward Van||Insider||Sell||12,000||$38.00||$456,000.00|| |
|3/19/2015||Randel G Owen||CFO||Sell||50,000||$38.04||$1,902,000.00|| |
|3/16/2015||Richard J Schnall||Director||Buy||100,000||$36.73||$3,673,000.00|| |
|3/9/2015||Steven G Murphy||SVP||Sell||12,021||$36.03||$433,116.63|| |
|2/25/2015||William A Sanger||CEO||Sell||153,782||$37.50||$5,766,825.00|| |
|2/23/2015||William A Sanger||CEO||Sell||7,100||$37.54||$266,534.00|| |
|1/9/2015||William A Sanger||CEO||Sell||194,968||$37.52||$7,315,199.36|| |
|1/8/2015||Randel G Owen||CFO||Sell||200,000||$36.56||$7,312,000.00|| |
|10/31/2014||Randel G Owen||CFO||Sell||19,180||$35.00||$671,300.00|| |
|10/28/2014||Randel G Owen||CFO||Sell||30,820||$35.00||$1,078,700.00|| |
|10/24/2014||Todd G Zimmerman||CEO||Sell||125,000||$35.00||$4,375,000.00|| |
|10/22/2014||Horne Edward Van||Insider||Sell||6,540||$35.00||$228,900.00|| |
|10/6/2014||Horne Edward Van||Insider||Sell||10,200||$35.00||$357,000.00|| |
|10/1/2014||Horne Edward Van||Insider||Sell||10,606||$34.67||$367,710.02|| |
|9/29/2014||Dighton Packard||Insider||Sell||32,400||$34.97||$1,133,028.00|| |
|9/29/2014||Michael L Smith||Director||Sell||7,000||$34.97||$244,790.00|| |
|9/29/2014||Randel G Owen||CFO||Sell||150,000||$34.97||$5,245,500.00|| |
|9/29/2014||Steve W Ratton Jr||EVP||Sell||25,000||$34.97||$874,250.00|| |
|9/29/2014||William A Sanger||CEO||Sell||200,000||$34.97||$6,994,000.00|| |
|9/15/2014||Steven G Murphy||SVP||Sell||45,988||$34.75||$1,598,083.00|| |
|7/16/2014||Horne Edward Van||Insider||Sell||20,269||$32.90||$666,850.10|| |
|7/16/2014||Leonard M Riggs Jr||Director||Sell||15,000||$32.90||$493,500.00|| |
|7/16/2014||Randel G Owen||CFO||Sell||249,375||$32.90||$8,204,437.50|| |
|7/16/2014||Steve W Ratton Jr||EVP||Sell||42,948||$32.90||$1,412,989.20|| |
|7/16/2014||Steven G Murphy||SVP||Sell||21,852||$32.90||$718,930.80|| |
|7/16/2014||William A Sanger||CEO||Sell||543,900||$32.90||$17,894,310.00|| |
|8/19/2013||Leonard M Riggs Jr||Director||Buy||44,000||$23.00||$1,012,000.00|| |
|8/19/2013||Steven G Murphy||SVP||Buy||5,000||$23.00||$115,000.00|| |
Envision Healthcare (NYSE EVHC) News Headlines
Envision Healthcare (NYSE:EVHC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Envision Healthcare (NYSE:EVHC) Income Statement, Balance Sheet and Cash Flow Statement
Envision Healthcare (NYSE EVHC) Stock Chart for Saturday, April, 21, 2018